Evgen Pharma PLC SFX-01 data published in Peer Reviewed Journal
August 02 2017 - 7:00AM
RNS Non-Regulatory
TIDMEVG
Evgen Pharma PLC
02 August 2017
For immediate release 2 August 2017
RNS Reach
Evgen Pharma plc
("Evgen Pharma" or "the Company")
SFX-01 data published in Peer Reviewed Journal
Evgen Pharma's SFX-01 protects against gait anomalies and
modifies bone microarchitecture in the spontaneous STR/Ort model of
osteoarthritis
Evgen Pharma (AIM: EVG), a clinical stage drug development
company focused on the treatment of cancer and neurological
conditions, is pleased to announce the publication in a peer
reviewed scientific journal of its lead product, SFX-01 and its
protective effects against osteoarthritis.
The paper, "Stable sulforaphane protects against gait anomalies
and modifies bone microarchitecture in the spontaneous STR/Ort
model of osteoarthritis", has been published in the journal Bone
and describes the work undertaken by researchers to see how SFX-01
modifies gait, bone architecture and slows or reverses articular
cartilage destruction in a spontaneous osteoarthritis model in
mice.
The paper can be viewed at:
http://www.thebonejournal.com/article/S8756-3282(17)30263-6/fulltext?cc=y=
(Behzad Javaheri et al; Stable sulforaphane protects against gait
anomalies and modifies bone microarchitecture in the spontaneous
STR/Ort model of osteoarthritis, Bone, 2017).
This follows the news in the AGM Statement announced on 26 July
2017, that Evgen, together with the RVC, University of London, has
secured grant funding to continue its collaboration to build on
this, now published, preclinical data demonstrating the potential
of SFX-01 as a treatment for osteoarthritis.
Enquiries:
Evgen Pharma plc c/o +44 (0) 20 7466
Dr Stephen Franklin, CEO 5000
Richard Moulson, CFO
www.evgen.com
Buchanan
Mark Court, Sophie Cowles, Stephanie +44 (0) 20 7466
Watson 5000
Northland Capital Partners Limited
Matthew Johnson, Gerry Beaney,
Margarita Mitropoulou (Corporate
Finance)
John Howes, Rob Rees (Corporate +44 (0) 20 3861
Broking) 6625
Notes for editors:
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company whose
lead programmes are in breast cancer and subarachnoid haemorrhage,
a type of stroke. It is also carrying out preclinical work in
multiple sclerosis and has a clinical interest in prostate cancer.
The Company's core technology is Sulforadex(R), a method for
synthesising and stabilising the naturally occurring compound
sulforaphane and novel proprietary analogues based on sulforaphane.
The lead product, SFX-01, is a patented composition of synthetic
sulforaphane and alpha-cyclodextrin.
Evgen Pharma commenced operations in January 2008 and has its
headquarters at The Colony, Wilmslow, Cheshire, and its registered
office is at the Liverpool Science Park, Liverpool. It joined the
AIM market of the London Stock Exchange in October 2015 and trades
under the ticker symbol EVG.
For further information, please visit: www.evgen.com
For commissioned research on the Company, please visit:
http://evgen.com/investors/analyst-coverage/
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAOKBDPDBKDDFK
(END) Dow Jones Newswires
August 02, 2017 08:00 ET (12:00 GMT)
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From Apr 2023 to Apr 2024